Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison

References

• Cardarelli WJ. Managed care aspects of managing neurogenic bladder/neurogenic detrusor overactivity. Am J Manag Care. 2013;19(10 Suppl):S205–S208.
   Web of Science ®Google Scholar
• Alsulihem A, Corcos J. Evaluation, treatment, and surveillance of neurogenic detrusor overactivity in spinal cord injury patients. Neuroimmunol Neuroinflammation. 2019;12(6):404–412.
   Google Scholar
• Yonnet GJ, Fjeldstad AS, Carlson NG, et al. Advances in the management of neurogenic detrusor overactivity in multiple sclerosis. Int J MS Care. 2013;15(2):66–72.
   PubMedGoogle Scholar
• Madersbacher H, Murtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51(6):432–441.
   PubMed Web of Science ®Google Scholar
• Ellsworth PI, Coyle PK, Esquenazi A, et al. Consensus statement on neurogenic detrusor overactivity: multiple sclerosis and spinal cord injury. 2012. Corpus ID: 59115883.
   Google Scholar
• Taweel WA, Seyam R. Neurogenic bladder in spinal cord injury patients. Res Rep Urol. 2015;7:85–99.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management. NICE guideline, published April 2, 2019. https://www.nice.org.uk/guidance/ng123/resources/urinary-incontinence-and-pelvic-organ-prolapse-in-women-management-pdf-66141657205189.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Lower urinary tract symptoms in men: management. NICE guideline, published May 23, 2010. https://www.nice.org.uk/guidance/cg97/resources/lower-urinary-tract-symptoms-in-men-management-pdf-975754394053
   Google Scholar
• Cruz F. Targets for botulinum toxin in the lower urinary tract. Neurourol Urodyn. 2014;33(1):31–38.
   PubMed Web of Science ®Google Scholar
• Thakker MM, Rubin PA. Pharmacology and clinical applications of botulinum toxins a and B. Int Ophthalmol Clin. 2004;44:147–163.
   PubMedGoogle Scholar
• Nitti VW. Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. Rev Urol. 2006;8(4):198–208.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration [Internet]. Prescribing information, BOTOX (onabotulinumtoxinA). 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103000s5236lbl.pdf
   Google Scholar
• Ipsen [Internet]. Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury. 2022. https://www.ipsen.com/press-releases/ipsen-receives-positive-opinion-in-europe-for-dysport-in-the-management-of-urinary-incontinence-in-adults-with-neurogenic-detrusor-overactivity-due-to-multiple-sclerosis-or-spinal-cord-injury/
   Google Scholar
• ClinicalTrials.gov [Internet]. Dysport® treatment of urinary incontinence in adults subjects with neurogenic detrusor overactivity (NDO) due to spinal cord injury or multiple sclerosis – study 1 (CONTENT1). 2021. https://clinicaltrials.gov/ct2/show/NCT02660138
   Google Scholar
• ClinicalTrials.gov [Internet]. Dysport® treatment of urinary incontinence in adults subjects with neurogenic detrusor overactivity (NDO) due to spinal cord injury or multiple sclerosis – study 2 (CONTENT2). 2021. https://clinicaltrials.gov/ct2/show/NCT02660359
   Google Scholar
• Denys P, Giannantoni AG, Thompson C, et al. Significant reduction of urinary incontinence episodes in patients with neurogenic detrusor overactivity treated with abobotulinumtoxinA (aboBoNT-a): pooled results of the phase III CONTENT program. Eur Urol. 2021;79(Suppl 1):S32–S33.
   Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429–437.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417–428.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. 2021. Accessed November 29, 2021.
   Google Scholar
• Homma Y, Koyama N. Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence. Neurourol Urodyn. 2006;25(3):228–235.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.
   PubMed Web of Science ®Google Scholar
• Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48.
   Web of Science ®Google Scholar
• Apostolidis A, Thompson C, Yan X, et al. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol. 2013;31(6):1469–1474.
   PubMed Web of Science ®Google Scholar
• Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–750.
   PubMed Web of Science ®Google Scholar
• Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–2139.
   PubMed Web of Science ®Google Scholar
• Schurch B, de Seze M, Denys P, Botox Detrusor Hyperreflexia Study Team, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200.
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Korn EL, Le-Rademacher J, et al. Clinical versus statistical significance in studies of thoracic malignancies. J Thorac Oncol. 2020;15(9):1406–1408.
   PubMed Web of Science ®Google Scholar
• Schober P, Bossers SM, Schwarte LA. Statistical significance versus clinical importance of observed effect sizes: what do P values and confidence intervals really represent? Anesth Analg. 2018;126(3):1068–1072.
   PubMed Web of Science ®Google Scholar